Edity Therapeutics

Edity Therapeutics, established in 2020, is a biotechnology startup hailing from Israel that is making waves with its pioneering approach to using human immune cells for delivering therapeutic proteins. The company's platform offers a revolutionary way to transfer these proteins to the target cells of patients, enabling precise modulation of intracellular pathways of diseases. By leveraging gene editors, immune sensors, enzymes, and intrabodies, Edity is at the forefront of advancing the potential for protein-based treatments. The startup recently secured a Seed Round investment on 12 July 2022, with backing from notable investors including Reinforced Ventures and NFX Bio. This injection of funding positions Edity Therapeutics to further develop its groundbreaking technology and drive impact within the realm of health and wellness, as well as medical devices.